
AstraZeneca inks $8.4B pact with Merck as crucial MYSTIC study fails and shares plunge
AstraZeneca’s crucial combination trial of durvalumab (Imfinzi) and tremelimumab has failed the primary endpoint on progression-free survival as a first-line therapy for non-small cell lung cancer. The shock waves from that news immediately ripped through its share price, erasing billions in market value and spurring some fevered speculation about the pharma giant’s future. And within hours analysts started to raise the prospect that the fallout just might be bad enough to inspire a new megamerger takeover attempt.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.